Global CAR T Cell Therapy Market, By Targeted Antigen, Therapeutic Application,
Posted by Rajkumar on April 2nd, 2019
In the recent past, cancer therapy such as targeted immunotherapies that includes CAR-T cell therapies is been preferred over surgery, chemotherapy, and radiation. These target cancer cells and strengthen the patient’s immune system against the tumor. CAR-T cell therapy is a type of treatment in which T-cells derived from patient’s blood are modified in laboratory with the addition of a special protein receptor on the T-cells that attack cancer cells. This special receptor is known as Chimeric Antigen Receptor (CAR) that binds to specific protein on patient’s cancer cells. Millions of CAR-T cells are grown in the laboratory and then administered in the patients through infusion. These cells bind to the infected cancer cells and have the ability to kill them thereby leading to curing of the cancer. Masking of cancer cells from immune cells can be combated by the incorporation of immune checkpoint inhibitors in body which can detect and inhibit cancer cells. This innovative approach of using the body’s immune cells to target cancer causing cells has been successful used in the treatment of pediatric relapsed acute lymphoblastic leukemia, refractory non-Hodgkin lymphoma, and other cancers.
For In depth Information Get Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/102
The global CAR-T Cell therapy market is estimated to be valued at US$ 295.1 million in 2018 and is expected to witness a CAGR of 32.5 % over the forecast period (2018 – 2028).
CAR-T cell therapy is expected to be an important development in cancer treatment and therapeutics industry due to its cost efficiency. Moreover, rising incidence of cancer is leading to high demand for its treatment. According to the World Cancer Research Fund International (WCRFI), around 14.1 million cancer cases were reported worldwide, in 2012. As per WCRFI, it is projected that by 2035, around 24 million cancer cases would be observed worldwide. Moreover, introduction of new therapies into the market is further expected to bolster growth of CAR-T cell therapy market. For instance, in October 2017, the U.S. Food and Drug Administration granted marketing approval to Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma. However, risks of side effects resulting in various neurological disorders is expected to hinder growth of the global CAR-T cell therapy market.
Increasing incidence of cancer and rising number of patients showing response failure to alternative treatments is expected to foster growth of the global CAR-T cell therapy market. Rising number of adults and children developing cancer is expected to lead to high demand for an effective and reliable therapeutic treatment approach for improvement of quality of patient’s lives. The Cancer Research UK reported that over 14.1 million cancer cases occurred in 2012 across the world. Moreover, according to the Leukemia and Lymphoma Society of Canada, around 22,340 people in Canada were diagnosed with some form of blood cancer, of which 9,000 cases were lymphoma.
Moreover, development of new and effective therapy options to cure symptoms of the disease is also a vital factor contributing to growth of CAR-T cell therapy market. In 2017, the U.S. Food and Drug Administration approved two CAR-T cell therapies Kymriah and Yescarta for children and adult lymphoblastic leukemia and advanced lymphoma in adults, respectively. This is expected to aid in growth of the market over the forecast period.
Market players are engaged in developing and launching innovative products and adopt merger and acquisition strategies to retain position in the global CAR-T cell therapy market
Key players in the market are engaged in extensive research and development to launch new targeted cell therapies in the market. For instance, the University of Texas MD Anderson Cancer Center, Houston is conducting phase 1 clinical trial studies of central memory–derived CD19 CAR T–cell therapy for relapsed intermediate-grade B-cell non-Hodgkin lymphoma. Moreover, key players are focusing on strategic merger and acquisition to enhance their share in the global CAR-T cell therapy market. For instance, in April 2018, Pfizer, Inc. signed a deal with Allogene, to develop an investigational CAR-T cell therapy for treating cancer.
Key players operating in the global CAR-T cell therapy market include Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Juno Therapeutics (Celgene Corporation), Bluebird Bio, Inc. (Celgene Corporation), Sorrento Therapeutics Inc., Mustang Bio, Inc., Aurora Biopharma Inc., Legend Biotech (Genscript Biotech Corporation), Pfizer, Inc., CARsgen Therapeutics, Ltd., and others.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Like it? Share it!
About the AuthorRajkumar
Joined: February 13th, 2019
Articles Posted: 590
More by this author